How to buy Zymeworks stock | $29.3

Zymeworks Inc is a biotechnology business based in the US. Zymeworks shares (ZYME) are listed on the NYSE and all prices are listed in US Dollars. Zymeworks employs 383 staff and has a trailing 12-month revenue of around 0.00.

Zymeworks stock price (NYSE: ZYME)

Use our graph to track the performance of ZYME stocks over time.

Zymeworks shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$29.30
52-week range	$24.82 - $59.03
50-day moving average	$36.33
200-day moving average	$35.48
Wall St. target price	$55.46
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.63

Buy Zymeworks shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Zymeworks stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Zymeworks Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zymeworks price performance over time

Historical closes compared with the close of $29.3 from 2021-05-26

1 week (2021-07-20)	N/A
1 month (2021-07-01)	-21.41%
3 months (2021-04-30)	-9.90%
6 months (2021-01-27)	N/A

1 year (2020-07-27)	N/A
2 years (2019-07-27)	N/A
3 years (2018-07-27)	N/A
5 years (2016-07-27)	N/A

Zymeworks financials

Revenue TTM	$31.3 million
Gross profit TTM	$-129,583,000
Return on assets TTM	-21.8%
Return on equity TTM	-43.13%
Profit margin	0%
Book value	$8.17
Market capitalisation	$1.6 billion

TTM: trailing 12 months

Shorting Zymeworks shares

There are currently 1.5 million Zymeworks shares held short by investors – that's known as Zymeworks's "short interest". This figure is 4.3% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Zymeworks shares can be evaluated.

Zymeworks's "short interest ratio" (SIR)

Zymeworks's "short interest ratio" (SIR) is the quantity of Zymeworks shares currently shorted divided by the average quantity of Zymeworks shares traded daily (recently around 476102.46153846). Zymeworks's SIR currently stands at 3.25. In other words for every 100,000 Zymeworks shares traded daily on the market, roughly 3250 shares are currently held short.

However Zymeworks's short interest can also be evaluated against the total number of Zymeworks shares, or, against the total number of tradable Zymeworks shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zymeworks's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Zymeworks shares in existence, roughly 30 shares are currently held short) or 0.0388% of the tradable shares (for every 100,000 tradable Zymeworks shares, roughly 39 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zymeworks.

Find out more about how you can short Zymeworks stock.

Zymeworks share dividends

We're not expecting Zymeworks to pay a dividend over the next 12 months.

Zymeworks share price volatility

Over the last 12 months, Zymeworks's shares have ranged in value from as little as $24.82 up to $59.03. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zymeworks's is 0.9846. This would suggest that Zymeworks's shares are less volatile than average (for this exchange).

Zymeworks overview

Zymeworks Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd. ; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd. ; Daiichi Sankyo Co. , Ltd.

Frequently asked questions

What percentage of Zymeworks is owned by insiders or institutions?
Currently 4.162% of Zymeworks shares are held by insiders and 81.371% by institutions. How many people work for Zymeworks?
Latest data suggests 383 work at Zymeworks. When does the fiscal year end for Zymeworks?
Zymeworks's fiscal year ends in December. Where is Zymeworks based?
Zymeworks's address is: 1385 West 8th Avenue, Vancouver, BC, Canada, V6H 3V9 What is Zymeworks's ISIN number?
Zymeworks's international securities identification number is: CA98985W1023 What is Zymeworks's CUSIP number?
Zymeworks's Committee on Uniform Securities Identification Procedures number is: 98985W102